Brain concussions are a serious public concern and are associated with neuropsychiatric disorders, such as depression. Patients with concussion who suffer from depression often experience distress. Nevertheless, few pre-clinical studies have examined concussion-induced depression, and there is little information regarding its pharmacological management. Edaravone, a free radical scavenger, can exert neuroprotective effects in several animal models of neurological disorders. However, the effectiveness of edaravone in animal models of concussion-induced depression remains unclear. In this study, we examined whether edaravone could prevent concussion-induced depression. Mice were subjected to a weight-drop injury and intravenously administered edaravone (3.0 mg/kg) or vehicle immediately after impact. Serial magnetic resonance imaging showed no abnormalities of the cerebrum on diffusion T1- and T2-weighted images. We found that edaravone suppressed concussion-induced depressive-like behavior in the forced swim test, which was accompanied by inhibition of increased hippocampal and cortical oxidative stress (OS) and suppression of 5-lipoxygenase (5-LOX) translocation to the nuclear envelope in hippocampal astrocytes. Hippocampal OS in concussed mice was also prevented by the nicotinamide adenine dinucleotide phosphate oxidase inhibitor, apocynin, and administration of BWB70C, a 5-LOX inhibitor, immediately and 24 h after injury prevented depressive-like behaviors in concussed mice. Further, antidepressant effects of edaravone were observed in mice receiving 1.0 or 3.0 mg/kg of edaravone immediately after impact, but not at a lower dose of 0.1 mg/kg. This antidepressant effect persisted up to 1 h after impact, whereas edaravone treatment at 3 h after impact had no effect on concussion-induced depressive-like behavior. These results suggest that edaravone protects against concussion-induced depression, and this protection is mediated by suppression of OS and 5-LOX translocation.
Get full access to this article
View all access options for this article.
References
1.
WhitnallL., McMillanT.M., MurrayG.D., and TeasdaleG.M. (2006). Disability in young people and adults after head injury: 5–7 year follow up of a prospective cohort study. J. Neurol. Neurosurg. Psychiatry, 77, 640–645.
2.
PandeyD.K., YadavS.K., MaheshR., and RajkumarR. (2009). Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety?. Behav. Brain Res., 205, 436–442.
3.
SilverJ.M., McAllisterT.W., and ArciniegasD.B. (2009). Depression and cognitive complaints following mild traumatic brain injury. Am. J. Psychiatry., 166, 653–661.
4.
KibbyM.Y., and LongC.J. (1996). Minor head injury: attempts at clarifying the confusion. Brain Inj., 10, 159–186.
5.
Pérez-NievasB.G., García-BuenoB., CasoJ.R., MenchénL., and LezaJ.C. (2007). Corticosterone as a marker of susceptibility to oxidative/nitrosative cerebral damage after stress exposure in rats. Psychoneuroendocrinology, 32, 703–711.
6.
BeckmanJ.S., BeckmanT.W., ChenJ., MarshallP.A., and FreemanB.A. (1990). Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U. S. A., 87, 1620–1624.
7.
AvilaM.A., SellS.L., KadoiY., ProughD.S., HellmichH.L., VelascoM., and DewittD.S. (2008). L-Arginine decreases fluid-percussion injury-induced neuronal nitrotyrosine immunoreactivity in rats. J. Cereb. Blood Flow Metab., 28, 1733–1741.
8.
WadaK., ChatzipanteliK., KraydiehS., BustoR., and DietrichW.D. (1998). Inducible nitric oxide synthase expression after traumatic brain injury and neuroprotection with aminoguanidine treatment in rats. Neurosurgery, 43, 1427–1436.
9.
CherianL., GoodmanJ.C., and RobertsonC.S. (2000). Brain nitric oxide changes after controlled cortical impact injury in rats. J. Neurophysiol., 83, 2171–2178.
10.
AhnM.J., SherwoodE.R., ProughD.S., LinC.Y., and DeWittD.S. (2004). The effects of traumatic brain injury on cerebral blood flow and brain tissue nitric oxide levels and cytokine expression. J. Neurotrauma, 21, 1431–1442.
11.
WhalenM.J., ClarkR.S., DixonC.E., RobichaudP., MarionD.W., VagniV., GrahamS.H., ViragL., HaskoG., StachlewitzR., SzaboC., and KochanekP.M. (1999). Reduction of cognitive and motor deficits after traumatic brain injury in mice deficient in poly(ADP-ribose) polymerase. J. Cereb. Blood Flow Metab., 19, 835–842.
12.
BessonV.C., CrociN., BouluR.G., PlotkineM., and Marchand-VerrecchiaC. (2003). Deleterious poly(ADP-ribose)polymerase-1 pathway activation in traumatic brain injury in rat. Brain Res., 989, 58–66.
13.
ForsterC., ClarkH.B., RossM.E., and IadecolaC. (1999). Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol., 97, 215–220.
14.
AllamF., DaoA.T., ChughG., BohatR., JafriF., PatkiG., MowreyC., AsgharM., AlkadhiK.A., and SalimS. (2013). Grape powder supplementation prevents oxidative stress-induced anxiety-like behavior, memory impairment, and high blood pressure in rats. J. Nutr., 143, 835–842.
15.
LiL.F., YangJ., MaS.P., and QuR. (2013). Magnolol treatment reversed the glial pathology in an unpredictable chronic mild stress-induced rat model of depression. Eur. J. Pharmacol., 711, 42–49.
16.
ZhouQ.G., ZhuL.J., ChenC., WuH.Y., LuoC.X., ChangL., and ZhuD.Y. (2011). Hippocampal neuronal nitric oxide synthase mediates the stress-related depressive behaviors of glucocorticoids by downregulating glucocorticoid receptor. J. Neurosci., 31, 7579–7590.
17.
ItohT., SatouT., NishidaS., TsubakiM., ImanoM., Hashimoto.S., and ItoH. (2010). Edaravone protects against apoptotic neuronal cell death and improves cerebral function after traumatic brain injury in rats. Neurochem, Res., 35, 348–355.
18.
WatanabeT., TaharaM., and TodoS. (2008). The novel antioxidant edaravone: from bench to bedside. Cardiovasc, Ther., 26, 101–114.
19.
KamidaT., AbeE., AbeT., OobaH., FujikiM., and KobayashiH. (2009). Edaravone, a free radical scavenger, retards the development of amygdala kindling in rats. Neurosci, Lett., 461, 298–301.
20.
OhtaM., HigashiY., YawataT., KitaharaM., NobumotoA., IshidaE., TsudaM., FujimotoY., and ShimizuK. (2013). Attenuation of axonal injury and oxidative stress by edaravone protects against cognitive impairments after traumatic brain injury. Brain Res., 1490, 184–192.
21.
ZhangL., ZhangW.P., HuH., WangM.L., ShengW.W., YaoH.T., DingW., ChenZ., and WeiE.Q. (2006). Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology, 26, 99–106.
22.
UzT., DimitrijevicN., ImbesiM., ManevH., and ManevR. (2008). Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice. Neurosci. Lett., 436, 269–272.
23.
LiC.T., ZhangW.P., LuY.B., FangS.H., YuanY.M., QiL.L., ZhangL.H., HuangX.J., and ZhangL., ChenZ., and WeiE.Q. (2009). Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells. J. Neurosci. Res., 87, 991–1001.
MilmanA., RosenbergA., WeizmanR., and PickC.G. (2005). Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice. J. Neurotrauma, 22, 1003–1010.
26.
RoyleS.J., CollinsF.C., RupniakH.T., BarnesJ.C., and AndersonR. (1999). Behavioural analysis and susceptibility to CNS injury of four inbred strains of mice. Brain Res., 816, 337–349.
27.
ShapiraY., YadidG., CotevS., and ShohamiE. (1989). Accumulation of calcium in the brain following head trauma. Neurol. Res., 11, 169–172.
28.
ElizaldeN., Gil-BeaF.J., RamírezM.J., AisaB., LasherasB., Del, RioJ., and TorderaR.M. (2008). Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment. Psychopharmacology, 199, 1–14.
29.
SmithP.K., KrohnR.I., HermansonG.T., MalliaA.K., GartnerF.H., ProvenzanoM.D., FujimotoE.K., GoekeN.M., OlsonB.J. and KlenkD.C. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76–85.
30.
BannoM., MizunoT., KatoH., ZhangG., KawanokuchiJ., WangJ., KunoR., JinS., TakeuchiH., and SuzumuraA. (2005). The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacology, 48, 283–290.
31.
DzitoyevaS., ImbesiM., UzT., DimitrijevicN., ManevH., and ManevR. (2008). Caffeic acid attenuates the decrease of cortical BDNF transcript IV mRNA induced by swim stress in wild-type but not in 5-lipoxygenase-deficient mice. J. Neural Transm., 115, 823–827.
32.
RådmarkO., WerzO., SteinhilberD., and SamuelssonB. (2007). 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci., 32, 332–341.
33.
HammarbergT., ProvostP., PerssonB., and RådmarkO. (2000). The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J. Biol. Chem., 275, 38787–38793.
34.
KulkarniS., DasS., FunkC.D., MurrayD., and ChoW. (2002). Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J. Biol. Chem., 277, 13167–13174.
35.
YeadonM., DouganF.L., PetrovicA., BeesleyJ.E., and PayneA.N. (1993). Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs. Agents Actions, 38, 8–18.
36.
LiC.T., ZhangW.P., FangS.H., LuY.B., ZhangL.H., QiL.L., HuangX.Q., HuangX.J., and WeiE.Q. (2010). Baicalin attenuates oxygen-glucose deprivation-induced injury by inhibiting oxidative stress-mediated 5-lipoxygenase activation in PC12 cells. Acta Pharmacol. Sin., 31, 137–144.
37.
LeeS.Y., LeeS.J., HanC., PatkarA.A., MasandP.S., and PaeC.U. (2013). Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry., 46, 224–235.
38.
CastrénE., VõikarV., and RantamäkiT. (2007). Role of neurotrophic factors in depression. Curr. Opin. Pharmacol., 7, 18–21.
39.
HsiehH.L., and YangC.M. (2013). Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed. Res. Int., 2013, 484613.
40.
SinghI.N., SullivanP.G., DengY., MbyeL.H., and HallE.D. (2006). Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J. Cereb. Blood Flow Metab., 26, 1407–1418.
41.
CooneyS.J., Bermudez-SabogalS.L., and ByrnesK.R. (2013). Cellular and temporal expression of NADPH oxidase (NOX) isotypes after brain injury. J. Neuroinflammation, 10, 155.
42.
ChoiB.Y., JangB.G., KimJ.H., LeeB.E., SohnM., SongH.K., and SuhS.W. (2012). Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase activation. Brain Res., 1481, 49–58.
43.
ZhangQ.G., LairdM.D., HanD., NguyenK., ScottE., DongY., DhandapaniK.M., and BrannD.W. (2012). Critical role of NADPH oxidase in neuronal oxidative damage and microglia activation following traumatic brain injury. PLoS One, 7, e34504.
44.
SeoJ.S., ParkJ.Y., ChoiJ., KimT.K., ShinJ.H., LeeJ.K., and HanP.L. (2012). NADPH oxidase mediates depressive behavior induced by chronic stress in mice. J. Neurosci., 32, 9690–9699.
45.
HärtigW., MichalskiD., SeegerG., VoigtC., DonatC.K., DulinJ., KaczaJ, MeixensbergerJ., ArendtT., and SchuhmannM.U. (2012). Impact of 5-lipoxygenase inhibitors on the spatiotemporal distribution of inflammatory cells and neuronal COX-2 expression following experimental traumatic brain injury in rats. Brain Res., 2012, Dec23. pii: S0006-8993(12)01933-6. doi: 10.1016/j.brainres.2012.12.022. [Epub ahead of print]
46.
IkonomovicM.D., AbrahamsonE.E., UzT., ManevH., and DekoskyS.T. (2008). Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J. Histochem. Cytochem., 56, 1065–1073.
47.
ErlemannK.R., RokachJ., and PowellW.S. (2004). Oxidative stress stimulates the synthesis of the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid by inflammatory cells. J. Biol. Chem., 279, 40376–40384.
48.
ErlemannK.R., CossetteC., GravelS., StamatiouP.B., LeeG.J., RokachJ., and PowellW.S. (2006). Metabolism of 5-hydroxy-6,8,11,14-eicosatetraenoic acid by human endothelial cells. Biochem. Biophys. Res. Commun., 350, 151–156.
49.
LammersC.H., SchweitzerP., FacchinettiP., ArrangJ.M., MadambaS.G., SigginsG.R., and PiomelliD. (1996). Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J. Neurochem., 66, 147–152.
50.
UzT., PesoldC., LongoneP., and ManevH. (1998). Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J., 12, 439–449.
51.
PengY.L., LiuY.N., LiuL., WangX., JiangC.L., and WangY.X. (2012). Inducible nitric oxide synthase is involved in the modulation of depressive behaviors induced by unpredictable chronic mild stress. J. Neuroinflammation, 9, 75.
52.
SilverJ.M., McAllisterT.W., and ArciniegasD.B. (2009). Depression and cognitive complaints following mild traumatic brain injury. Am. J. Psychiatry., 166, 653–661.
53.
SchwarzboldM.L., RialD., De BemT., MachadoD.G., CunhaM.P., dos SantosA.A., dos SantosD.B., FigueiredoC.P., FarinaM., GoldfederE.M., RodriguesA.L., PredigerR.D., and WalzR. (2010). Effects of traumatic brain injury of different severities on emotional, cognitive, and oxidative stress-related parameters in mice. J. Neurotrauma, 27, 1883–1893.
54.
ReddyC.C. (2011). Postconcussion syndrome: a physiatrist's approach. PM R., 3(10 Suppl. 2), S396–S405.
55.
ZoharO., RubovitchV., MilmanA., SchreiberS., and PickC.G. (2011). Behavioral consequences of minimal traumatic brain injury in mice. Acta Neurobiol. Exp., 71, 36–45.
56.
NaritomiH., MoriwakiH., MetokiN., NishimuraH., HigashiY., YamamotoY., YuasaH., OeH., TanakaK., SaitoK., TerayamaY., OdaT., TanahashiN., and KondoH. (2010). Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. Drugs R D., 10, 155–163.
57.
KawaiH., NakaiH., SugaM., YukiS., WatanabeT., and SaitoK. (1997). Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther., 281, 921–927.
58.
WatanabeT., YukiS., EgawaM., and NishiH. (1994). Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther., 268, 1597–1604.
59.
MallerJ.J., ThomsonR.H., LewisP.M., RoseS.E., PannekK., and FitzgeraldP.B. (2010). Traumatic brain injury, major depression, and diffusion tensor imaging: making connections. Brain Res. Rev., 64, 213–240.
